Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

Northwell Health75 enrolled

Overview

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

As above

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Pulmonary Arterial Hypertension

Interventions

Blood drawOTHER

Venous and Arterial Blood draw samples; 6 Minute Walk test

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization. * Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization. Exclusion Criteria: * Significant left heart disease or renal insufficiency (serum creatinine \> 1.5 mg%).

Locations (1)

North Shore-Long Island Health System

New Hyde Park, New York, United States

Outcomes

Primary Outcomes

Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH.

Time frame: 2 year

Secondary Outcomes

To determine if changes in plasma/arterial MIF levels pre/post 6MW test are due to MIF released from the lungs

Time frame: 2 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.